slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 92,761-92,790
Pages 3,683
Rows per page 30
Component
92,761-92,790 of 110,471
06
Matson | Results Presentation Deck | 10 slidesMatson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
07
The chart compares quarterly container volumes between 2022 and 2023.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
08
The chart compares 2022 vs 2023 quarterly container volumes.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
09
The chart shows quarterly container volume (FEU) for 2022 vs 2023.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
10
The chart shows quarterly operating income for 2022 and 2023, with Q4 2023 highlighted as a range.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
04
The slide uses a dual-track timeline (Cell Therapy and Drug Discovery) to show company evolution.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations 1 hit
08
The chart shows a cumulative growth trend of partner milestones over time, with logos placed in vertical columns representing years.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
09
Uses a stacked area chart to represent revenue components (instruments, milestones, sales-based payments) over time.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
10
The slide uses two donut charts to visualize the distribution of milestone events across IND, Pre-Pivotal, and Pivotal or Later phases.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
05
The chart shows revenue growth across three regions (Americas, EMEA, Asia) over three time points (2010, 2018, 2023).Morgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · What IsLoop · Benchmark Gap1 hit
06
The diagram uses a hub-and-spoke circular flow model to represent the firm's central role in the ecosystem.Morgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · What Could BeLoop · So What Cascade1 hit
11
Includes reconciliation table for Net Revenues and Pre-Tax Profit adjustments.Morgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · New Bliss1 hit
03
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Team1 hit
09
The diagram shows a biological pathway from steatosis to steatohepatitis to fibrosis, highlighting the role of GPR119 activation in modulating cellular responses.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
11
Includes specific study references and definitions for abbreviations like GPR119, MASH, and GLP-1.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
12
The slide presents 10 distinct bar charts comparing Control, DA, DA+DPP4i, and DPP4i groups, with statistical significance markers.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
The slide uses a diagram to map the drug's mechanism of action to specific biological effects in the liver, pancreas, and immune system.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
17
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of the hormone.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
20
Includes definitions for MAD, SAD, PK, PD, FPFV, and LPLV.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
10
Study identifier NST002, 15 patients, open-label, intermediate formulation.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
11
Includes details on screen failures and co-treatment with Riluzole.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
18
The slide uses icons to represent functional domains and provides specific clinical examples of what a 1-point change means for patient quality of life.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
22
The slide uses a series of blue blocks to represent different research pillars/methodologies within the PARADIGM trial.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
23
The slide uses a case study to validate the business model of combination therapies.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
26
The slide outlines the RoAD study parameters including patient population, dosing, and primary/secondary endpoints.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
09
Includes footnotes explaining specific line items and non-GAAP metrics.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
12
The chart illustrates the bridge between two balance sheet dates.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
15
The slide uses a combination of a bar-line chart for historical trends and a waterfall chart for the quarterly bridge.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
19
The slide highlights that NYCB remains well-capitalized despite ongoing goodwill impairment assessments.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
22
The slide displays a pie chart of loan distribution and a list of portfolio highlights including yield, historical losses, and criticized loan increases.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Solution1 hit